Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort studyShun Kohsaka, Dianna J. Magliano, Matthias Saathoff et al.|The Lancet Diabetes & Endocrinology|2020Cited by 93